Shockwave Medical, Inc.

Informe acción NasdaqGS:SWAV

Capitalización de mercado: US$12.3b

Shockwave Medical Resultados de beneficios anteriores

Pasado controles de criterios 2/6

Shockwave Medical ha aumentado sus ingresos a un ritmo medio anual de 73.5%, mientras que la industria Medical Equipment ha visto aumentar sus ingresos growing a 9.1% anualmente. Los ingresos han crecido growing a un ritmo medio anual de 63.5%. Shockwave Medical La rentabilidad de los fondos propios de la empresa es de 40.6% y sus márgenes netos son de 36.3%.

Información clave

68.6%

Tasa de crecimiento de los beneficios

81.9%

Tasa de crecimiento del BPA

Crecimiento de la industria Medical Equipment 8.9%
Tasa de crecimiento de los ingresos60.2%
Rentabilidad financiera22.0%
Margen neto20.2%
Próxima actualización de resultados06 May 2024

Actualizaciones de resultados anteriores recientes

Shockwave Medical's (NASDAQ:SWAV) Earnings Aren't As Good As They Appear

Mar 06
Shockwave Medical's (NASDAQ:SWAV) Earnings Aren't As Good As They Appear

Recent updates

Shockwave Medical, Inc.'s (NASDAQ:SWAV) 28% Jump Shows Its Popularity With Investors

Apr 06
Shockwave Medical, Inc.'s (NASDAQ:SWAV) 28% Jump Shows Its Popularity With Investors

Is Now An Opportune Moment To Examine Shockwave Medical, Inc. (NASDAQ:SWAV)?

Mar 24
Is Now An Opportune Moment To Examine Shockwave Medical, Inc. (NASDAQ:SWAV)?

Shockwave Medical: Opening Arteries, Delivering Returns

Feb 28

Shockwave Medical, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Feb 18
Shockwave Medical, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

There's Been No Shortage Of Growth Recently For Shockwave Medical's (NASDAQ:SWAV) Returns On Capital

Feb 06
There's Been No Shortage Of Growth Recently For Shockwave Medical's (NASDAQ:SWAV) Returns On Capital

Calculating The Fair Value Of Shockwave Medical, Inc. (NASDAQ:SWAV)

Jan 24
Calculating The Fair Value Of Shockwave Medical, Inc. (NASDAQ:SWAV)

Some Shareholders Feeling Restless Over Shockwave Medical, Inc.'s (NASDAQ:SWAV) P/E Ratio

Jan 09
Some Shareholders Feeling Restless Over Shockwave Medical, Inc.'s (NASDAQ:SWAV) P/E Ratio

Is Shockwave Medical (NASDAQ:SWAV) A Risky Investment?

Dec 27
Is Shockwave Medical (NASDAQ:SWAV) A Risky Investment?

Do Shockwave Medical's (NASDAQ:SWAV) Earnings Warrant Your Attention?

Dec 13
Do Shockwave Medical's (NASDAQ:SWAV) Earnings Warrant Your Attention?

What Is Shockwave Medical, Inc.'s (NASDAQ:SWAV) Share Price Doing?

Nov 17
What Is Shockwave Medical, Inc.'s (NASDAQ:SWAV) Share Price Doing?

Is Shockwave Medical, Inc. (NASDAQ:SWAV) Trading At A 50% Discount?

Oct 19
Is Shockwave Medical, Inc. (NASDAQ:SWAV) Trading At A 50% Discount?

Shockwave Medical (NASDAQ:SWAV) Is Very Good At Capital Allocation

Oct 06
Shockwave Medical (NASDAQ:SWAV) Is Very Good At Capital Allocation

Shockwave Medical (NASDAQ:SWAV) Has A Rock Solid Balance Sheet

Sep 20
Shockwave Medical (NASDAQ:SWAV) Has A Rock Solid Balance Sheet

Do Shockwave Medical's (NASDAQ:SWAV) Earnings Warrant Your Attention?

Sep 07
Do Shockwave Medical's (NASDAQ:SWAV) Earnings Warrant Your Attention?

When Should You Buy Shockwave Medical, Inc. (NASDAQ:SWAV)?

Jul 10
When Should You Buy Shockwave Medical, Inc. (NASDAQ:SWAV)?

We Think Shockwave Medical (NASDAQ:SWAV) Might Have The DNA Of A Multi-Bagger

Jun 26
We Think Shockwave Medical (NASDAQ:SWAV) Might Have The DNA Of A Multi-Bagger

We Think Shockwave Medical (NASDAQ:SWAV) Can Manage Its Debt With Ease

Jun 13
We Think Shockwave Medical (NASDAQ:SWAV) Can Manage Its Debt With Ease

Is Now The Time To Put Shockwave Medical (NASDAQ:SWAV) On Your Watchlist?

May 29
Is Now The Time To Put Shockwave Medical (NASDAQ:SWAV) On Your Watchlist?

The Trend Of High Returns At Shockwave Medical (NASDAQ:SWAV) Has Us Very Interested

Mar 27
The Trend Of High Returns At Shockwave Medical (NASDAQ:SWAV) Has Us Very Interested

Shockwave Medical's (NASDAQ:SWAV) Earnings Aren't As Good As They Appear

Mar 06
Shockwave Medical's (NASDAQ:SWAV) Earnings Aren't As Good As They Appear

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Shockwave Medical. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).


Historial de beneficios e ingresos

NasdaqGS:SWAV Ingresos, gastos y beneficios (USD Millions)
FechaIngresosBeneficiosGastos G+AGastos de I+D
31 Dec 23730147323146
30 Sep 23671244293127
30 Jun 23617244277108
31 Mar 2355724124492
31 Dec 2249021621982
30 Sep 224308820173
30 Jun 223645518366
31 Mar 222992916357
31 Dec 21237-914651
30 Sep 21176-3812645
30 Jun 21130-5310839
31 Mar 2184-719035
31 Dec 2068-667637
30 Sep 2059-656738
30 Jun 2051-655938
31 Mar 2051-575337
31 Dec 1943-514533
30 Sep 1934-483729
30 Jun 1926-453226
31 Mar 1918-442825
31 Dec 1812-412423
31 Dec 172-311218

Ingresos de calidad: SWAV tiene ganancias de alta calidad.

Margen de beneficios creciente: SWAVLos actuales márgenes de beneficio netos de (20.2%) son inferiores a los del año pasado (44.1%).


Análisis del flujo de caja libre vs. Beneficios


Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: SWAV se ha vuelto rentable en los últimos 5 años, con un crecimiento de los beneficios de 73.5% al año.

Acelerando crecimiento: SWAV's ha tenido un crecimiento negativo de los beneficios en el último año, por lo que no puede compararse con su media de 5 años.

Beneficios vs. Industria: SWAV tuvo un crecimiento negativo de los beneficios (-31.8%) durante el año pasado, lo que dificulta la comparación con la media del sector Medical Equipment (7.8%).


Rentabilidad financiera

Alta ROE: Aunque la Rentabilidad de los fondos propios de SWAV(22.03%) es alta, esta métrica está sesgada debido a su elevado nivel de endeudamiento.


Rentabilidad económica


Rendimiento del capital invertido


Descubre empresas con buenos resultados en el pasado

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target